AYTU - Aytu BioScience, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.9040
-0.0145 (-1.58%)
At close: 3:56PM EST
Stock chart is not supported by your current browser
Previous Close0.9185
Open0.9400
Bid0.903 x 1000
Ask1.000 x 3000
Day's Range0.9040 - 0.9500
52 Week Range0.7900 - 85.2000
Volume73,990
Avg. Volume667,732
Market Cap7.805M
Beta (3Y Monthly)5.95
PE Ratio (TTM)N/A
EPS (TTM)-21.193
Earnings DateFeb 7, 2018 - Feb 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • ACCESSWIRE9 days ago

    Aytu BioScience Announces Commercial Availability of Tuzistra(R) XR (codeine polistirex and chlorpheniramine polistirex) oral suspension

    Nationwide availability for the first and only codeine-based, extended-release, oral-suspension cough/cold treatment in U.S. ENGLEWOOD, CO / ACCESSWIRE / December 6, 2018 / Aytu BioScience, Inc. (NASDAQ: ...

  • ACCESSWIRE11 days ago

    Aytu BioScience Provides Webcast Information for 2018 LD Micro Conference Presentation

    ENGLEWOOD, CO / ACCESSWIRE / December 4, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today provided webcast information for the Company's upcoming presentation at the 11th Annual LD Micro Main Event investor conference. Josh Disbrow, Aytu BioScience's Chief Executive Officer and David Green, Aytu BioScience's Chief Financial Officer, will be presenting at the conference on Wednesday, December 5, 2018 at 9:00 am PT/12:00 pm ET at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

  • ACCESSWIRE12 days ago

    Aytu BioScience Announces Appointment of Two New Directors, Steven Boyd and Ketan Mehta

    ENGLEWOOD, CO / ACCESSWIRE / December 3, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced two new appointments to the Company's board of directors. Ketan Mehta, Founder and Chief Executive Officer of Tris Pharma joined the board effective November 30, 2018. Steven Boyd, Founder and Chief Investment Officer of Armistice Capital, is expected to be appointed to the board of directors at an upcoming board meeting in the first calendar quarter of 2019.

  • ACCESSWIRE15 days ago

    Aytu BioScience Announces Closing of $5M Investment from Armistice Capital

    ENGLEWOOD, CO / ACCESSWIRE / November 30, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the closing of a strategic investment in the company by Armistice Capital ("Armistice"). Armistice has invested $5 million in the form of a three-year senior secured note. This investment by Armistice has been made in conjunction with the company's licensing of Tuzistra® XR and a complementary antitussive pending FDA approval and is intended to further support the growth of the company's commercial portfolio.

  • GlobeNewswire29 days ago

    Investor Expectations to Drive Momentum within ANGI Homeservices, Aytu Bioscience, IRIDEX, Cellular Biomedicine Group, CounterPath, and EXFO — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRElast month

    Aytu BioScience Announces Positive Interim Results from Natesto(R) Spermatogenesis Study

    Fertility Preserved in Hypogonadal Men Taking Natesto, Based on Semen Analyses Conducted at Three-Month and Six-Month Timepoints ENGLEWOOD, CO / ACCESSWIRE / November 15, 2018 / Aytu BioScience, Inc. (NASDAQ: ...

  • ACCESSWIRElast month

    Aytu BioScience to Report Interim Results from Natesto(R) Spermatogenesis Study on Thursday, November 15, 2018

    Live Conference Call and Webcast Scheduled for 5:00 p.m. ET on November 15, 2018 Presentation of Interim Analysis by Dr. Ranjith Ramasamy, MD, Director of Reproductive Urology and Assistant Professor, ...

  • ACCESSWIRElast month

    Aytu BioScience Reports 55% Sequential Revenue Growth in Q1 FY19; Adds Tuzistra(R) XR to Portfolio

    Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE / November 7, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization ...

  • ACCESSWIRElast month

    Biotech Stocks and the Midterm Elections

    HENDERSON, NV / ACCESSWIRE / November 7, 2018 / Midterm elections are expected to result in a split Congress, which should increase predictability for the biotech industry, and prevent, what some see as disruptive, government dictated pricing, less likely than if there is a Congress controlled by one party. Propanc Biopharma, Inc. (PPCB) is one biotech firm you should look at today. The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer.

  • ACCESSWIRElast month

    Aytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Tuzistra(R) XR

    ENGLEWOOD, CO / ACCESSWIRE / November 5, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the Company's entry into the $3 billion cough and cold market with an exclusive license of FDA-approved Tuzistra® XR from Tris Pharma. Tuzistra XR is the only FDA-approved 12-hour codeine-based antitussive.

  • ACCESSWIRElast month

    Aytu BioScience to Report Fiscal First Quarter 2019 Results and Business Update

    Live Conference Call and Webcast Scheduled for November 7, 2018, at 4:30 p.m. ET ENGLEWOOD, CO / ACCESSWIRE / October 31, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company ...

  • These 16 public Colorado companies are concerned about tariffs, according to recent SEC filings
    American City Business Journals2 months ago

    These 16 public Colorado companies are concerned about tariffs, according to recent SEC filings

    While these companies might not've spoken out publicly on the topic of tariffs, they have noted their concerns in SEC filings.

  • ACCESSWIRE2 months ago

    Aytu BioScience Announces Issuance of First U.S. Patent Covering MiOXSYS(R) for Male Infertility; Company Progresses Toward U.S. Regulatory Clearance and Commercialization

    U.S. Patent Number 10,088,466 is Company's First United States Patent Covering MiOXSYS for Male Infertility Assessment ENGLEWOOD, CO / ACCESSWIRE / October 11, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), ...

  • ACCESSWIRE2 months ago

    Aytu BioScience Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

    ENGLEWOOD, CO / ACCESSWIRE / October 10, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the closing of an underwritten public offering on October 9, 2018, with total gross proceeds of $15.2 million which includes the full exercise of the underwriters' over-allotment option to purchase additional shares and warrants, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) an aggregate of 457,007 shares of its Common Stock, (ii) an aggregate of 8,342,993 shares of its Series C Convertible Preferred Stock convertible into an aggregate of 8,342,993 shares of Common Stock at a conversion price of $1.50 per share, and (iii) Warrants to purchase an aggregate of 8,800,000 shares of Common Stock at an exercise price of $1.50 per share.

  • MarketWatch2 months ago

    Aytu, KemPharm stocks plunge to pace Nasdaq decliners after share offerings

    Shares of Aytu BioScience Inc. plummeted 33% and of KemPharm Inc. plunged 32% Friday, to pace the Nasdaq's decliners, as both specialty pharmaceutical companies announced relatively large public share offerings that priced at deep discounts. KemPharm offered 8.33 million shares, representing 52% of the shares outstanding, that priced at $3.00 a share, or 28% below Thursday's closing price of $4.18. Meanwhile, Aytu offered 457,007 shares of common stock, 8.34 million shares of preferred stock convertible into 8.34 million shares of common stock at a conversion price of $1.50 per share, and warrants to buy and additional 8 million shares of common stock at an exercise price of $1.50 a share. That price was 26% below Thursday's closing price of $2.02. Aytu had 1.80 million shares outstanding as of Aug. 31. KemPharm shares have now lost 56% over the past three months and Aytu's stock has dropped 75%, while the S&P 500 has gained 6.1%.

  • ACCESSWIRE2 months ago

    Aytu BioScience Announces Pricing of $13.2 Million Underwritten Public Offering

    ENGLEWOOD, CO / ACCESSWIRE / October 5, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the pricing of an underwritten public offering with expected total gross proceeds of $13.2 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) an aggregate of 457,007 shares of its Common Stock, (ii) an aggregate of 8,342,993 shares of its Series C Convertible Preferred Stock convertible into an aggregate of 8,342,993 shares of Common Stock at a conversion price of $1.50 per share, and (iii) Warrants to purchase an aggregate of 8,800,000 shares of Common Stock at an exercise price of $1.50 per share.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Aytu Bioscience and Altimmune

    NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Shares of Altimmune were collapsing in Friday’s session as the company announced the pricing of an underwritten public offering. Shares of Aytu Biosciences were seeing gains of over 13% despite any significant news. Aytu BioScience, Inc. shares were up 13.11% on Friday on nearly 2.8 million shares traded.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Corbus Pharmaceuticals and Aytu Bioscience

    NEW YORK, NY / ACCESSWIRE / September 21, 2018 / Biotech stocks Corbus Pharmaceuticals and Aytu BiosScience were both roaring on Thursday. Shares of Corbus exploded on the news that it has expanded its target indications by adding over 600 compounds that are focused on the endocannabinoid system from Jenrin Discovery. Aytu BioScience didn’t have any news yesterday but earlier in the week provided a clinical trial update.

  • ACCESSWIRE3 months ago

    Aytu BioScience Announces Publication of Manuscript Summarizing Results from the Ongoing Natesto(R) Spermatogenesis Study

    ENGLEWOOD, CO / ACCESSWIRE / September 17, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the publication of a clinical trial update in the journal European Urology Focus on the effects of Natesto® on reproductive hormones and semen parameters. This study is being conducted at the University of Miami's Department of Urology, and Dr. Ranjith Ramasamy, MD, the Director of Reproductive Urology, is the study's principal investigator. The publication entitled, "Natesto Effects on Reproductive Hormones and Semen Parameters: Results from an Ongoing Single-center, Investigator-initiated Phase IV Clinical Trial" provides updated data on five of the 23 currently enrolled subjects, through six months of Natesto treatment.

  • ACCESSWIRE3 months ago

    Natesto(R) Q4 Revenue Increases 178% Sequentially; Q4 Product Revenue Increases 52% Sequentially

    Highest Ever Quarterly Net Revenue for Natesto Testosterone Nasal Gel ENGLEWOOD, CO / ACCESSWIRE / September 6, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on ...

  • ACCESSWIRE4 months ago

    Aytu BioScience to Report Fiscal Fourth Quarter 2018 Results and Business Update

    Live Conference Call and Webcast Scheduled for September 6, 2018, at 4:30 p.m. ET ENGLEWOOD, CO / ACCESSWIRE / August 30, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company ...

  • ACCESSWIRE4 months ago

    Aytu BioScience Announces Accelerated Launch of ZolpiMist(TM) in the U.S.

    ENGLEWOOD, CO / ACCESSWIRE / August 13, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the accelerated launch of ZolpiMist™, an oral spray formulation of zolpidem tartrate (brand name Ambien®) and the only FDA-approved oral spray prescription sleep aid. The Aytu BioScience sales force begins promoting ZolpiMist to U.S. clinicians today in the domestic $1.8 billion non-benzodiazepine prescription sleep aid market.

  • ACCESSWIRE4 months ago

    Aytu BioScience Announces Effectiveness of 1-for-20 Reverse Stock Split

    ENGLEWOOD, CO / ACCESSWIRE / August 10, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will effect a 1-for-20 reverse split of its issued and outstanding shares of common stock. The reverse stock split will become effective August 10, 2018 at 4:30 p.m. EDT. Shares of the company's common stock will trade on a split-adjusted basis beginning Monday, August 13, 2018.

  • ACCESSWIRE5 months ago

    Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • ACCESSWIRE5 months ago

    Aytu BioScience Announces Enrollment of First Twenty Patients in the Natesto(R) Spermatogenesis Study

    ENGLEWOOD, CO / ACCESSWIRE / July 17, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the first twenty patients have been enrolled in the company's investigator-initiated study assessing the impact of Natesto® on sperm production and gonadotropin levels. This study is being conducted at the University of Miami's Department of Urology, and Dr. Ranjith Ramasamy, MD, the Director of Reproductive Urology, is the study's principal investigator.